People assigned female at birth have a predisposition for migraines, especially in adolescence and around menopause. Find a ...

The following is a summary of “Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 ...

Migraine is a common neurological disorder manifesting as a headache However it has a complex pathophysiology involving the ...

A groundbreaking study has uncovered new insights into the pain pathways associated with temporomandibular joint (TMJ) disorders.

Any changes in routine-time changes, travel, earlier wake up times, can trigger a migraine. People who suffer with migraine ...

Migraine disrupts daily life with invisible neurological pain, causing physical, emotional, and cognitive struggles that go ...

The NICE recommendation of Vyepti as a comparator to other treatments in the CGRP inhibitor class provides another option for people living with episodic or chronic migraine, particularly those ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

Data from the Phase III EMERGE trial show treatment with Symbravo provided more rapid and sustained migraine relief with improved quality of life in patients who previously had an inadequate response ...

The global market for acute migraine treatment is on a steady growth trajectory, with sales expected to rise from USD 2,700.7 million in 2024 to USD 4,194.1 million by 2034, reflecting a CAGR of 4.5% ...

A migraine isn't only a headache. It's a complex web of symptoms that can affect your whole body. Doctors used to think that a migraine attack happened only because blood vessels in your brain ...

47.9% of patients reported sustained pain relief for 24 hours with Symbravo, compared to 16.7% with oral CGRP inhibitors. In the trial, Symbravo rapidly and substantially improved migraine pain ...